Clipos™ CTLA-4-TF tag mRNA Lipid Nanoparticles

Catalog:CDL23-070-L

Unit Size:200 μL

INQUIRY Datasheet

Specifications
Description CTLA-4 (cytotoxic T lymphocyte-associated protein 4), also known as CD152, is a protein receptor of the immunoglobulin superfamily. It is encoded by the CTLA4 gene and is constitutively expressed in regulatory T cells. The protein contains an extracellular V domain, a transmembrane domain and a cytoplasmic tail. Alternative transcriptional splice variants encoding different isoforms have been characterized. The membrane-bound isoform acts as a homodimer interconnected by disulfide bonds, while the soluble isoform acts as a monomer. The function of CTLA-4 is thought to be the recruitment of phosphatases to the T cell receptor (TCR). CTLA-4 also functions to capture and remove CD80 and CD86 from antigen-presenting cell membranes, making them unable to trigger CD2. As an immune checkpoint, CTLA-4 has attracted great interest in immunotherapy of cancer patients. Ipilimumab, an antagonistic antibody against CTLA, is the first immune checkpoint blockade therapy approved by the FDA for the treatment of cancer. This product is designed as a tool for the delivery and expression of human TF tagged CTLA-4 mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of CTLA-4-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The CTLA-4-TF fusion protein is approximately 23 kD, consisting of mature CTLA-4 (188 amino acids) and a C-terminal TF tag (15 amino acids)
Lipid composition SM-102/DSPC/Cholesterol/DMG-PEG2000
Encoding mRNA CTLA4
In Vitro QC (Cell Types) HEK293S
Technology Applications Protein research
Storage Store at 4°C
Technical Notes Work with mRNA-LNP on ice. It is important to minimize the time that the product spends at room temperature; after handling product during experiments, return immediately to ice.Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container; it is important not to spin for too long as this may rupture mRNA-LNP’s. Do not vortex. mRNA-LNP products should only be handled with certified RNAase-free reagents and consumables; use of filtered pipette tips is highly recommended
Related Products
Product Name Catalog Lipid composition Liposome Size Price
Clipos™ EGFP mRNA Lipid Nanoparticles CDPM01 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ mCherry mRNA Lipid Nanoparticles CDPM02 INQUIRY
Clipos™ mCherry-Luciferase mRNA Lipid Nanoparticles CDPM03 INQUIRY
Clipos™ Luciferase mRNA Lipid Nanoparticles CDPM04 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ CAS 9-RNA Lipid Nanoparticles-HA CDPM05 INQUIRY
Clipos™ ANTI-BCMA mRNA Lipid Nanoparticles CDPM06 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ ANTI-CD19 mRNA Lipid Nanoparticles CDPM07 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ ANTI-HER2 mRNA Lipid Nanoparticles CDPM08 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Products
Fill out the form below
to receive a quote

GET A QUOTE

Services

Drug Targeting Strategy

Drug Delivery Nanoparticles Formulation

Bioparticles Analysis and Characterization

Bioactive Particles & Fillers Production

Functional Biomedical Coatings

Lipid Library Development for Drug Delivery

Aptamer Targeted Drug Delivery System

Other Types of Drug Delivery

Products

Liposome System

Chelating Agents

Bioactive Matrixes

Porous Organic Materials

Biopolymers & Synthetic Polymers

PROTAC

Transfection

Exosome Products

Cleavable Linkers

Pharmaceutical Excipients (drug/medical grade)

Tissue Engineering Scaffold

  • (USA)
  • (Europe)
Cookie Policy | Privacy Policy | Copyright © 2024 CD Bioparticles. All rights reserved.
0
Inquiry Basket
Inquiry